Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming 2024 ASCO Genitourinary Cancers Symposium (ASCO GU) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Sub-group analysis from Blue Earth Diagnostics’ Phase 3 LIGHTHOUSE trial highlights POSLUMA utility to guide treatment selection and potentially avoid futile surgery
New Data on POSLUMA® (Flotufolastat F 18) in Patients with Suspected Biochemical Recurrence of Prostate Cancer and Low-Very Low Prostate Specific Antigen (PSA) Levels Presented at ASTRO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered –For U.S audiences onlyMONROE TOWNSHIP, N.J. & OXFORD, England (BUSINESS WIRE) Blue Earth Diagnostics, a Bracco company and recognized leader in.
Additional Results of POSLUMA® (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.